Compare FTK & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTK | LBRX |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 522.1M | 602.6M |
| IPO Year | 1997 | N/A |
| Metric | FTK | LBRX |
|---|---|---|
| Price | $16.88 | $31.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $20.00 | ★ $46.60 |
| AVG Volume (30 Days) | 201.9K | ★ 298.3K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 147.06 | N/A |
| EPS | ★ 0.84 | N/A |
| Revenue | ★ $136,092,000.00 | N/A |
| Revenue This Year | $13.33 | N/A |
| Revenue Next Year | $16.38 | N/A |
| P/E Ratio | $20.71 | ★ N/A |
| Revenue Growth | ★ 214.53 | N/A |
| 52 Week Low | $6.68 | $13.40 |
| 52 Week High | $20.41 | $33.47 |
| Indicator | FTK | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 53.87 | 65.84 |
| Support Level | $15.89 | $21.90 |
| Resistance Level | $17.67 | N/A |
| Average True Range (ATR) | 0.82 | 2.05 |
| MACD | 0.17 | 0.31 |
| Stochastic Oscillator | 69.33 | 78.66 |
Flotek Industries Inc is a technology-driven specialty chemistry and data company. It has two reportable segments: Its Chemistry Technologies segment includes specialty chemistries, logistics and technology services. It also include integrated oil and gas companies, oilfield services companies, independent oil and gas companies, national and state-owned oil companies, and international supply chain management companies. The Data Analytics segment provides analytical measurement solutions and deliver real-time information and insights to customers to enable optimization of operations and reduction of emissions and their carbon intensity. Key revenue comes from its Chemistry Technologies segment.
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.